Lionco Pharmaceutical Group Co (SHSE:603669) Total Liabilities: ¥498.4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603669 Lionco Pharmaceutical Group Co Ltd SHSE:603669
59 GF Score
Price ¥5.04
GF Value ¥6.83
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lionco Pharmaceutical Group Co Total Liabilities?

Lionco Pharmaceutical Group Co SHSE:603669 -3.08% 59 Total Liabilities is ¥498.4 Mil as of Mar. 2026. GuruFocus rates SHSE:603669 with a GF Score™ of 59/100 and a GF Value™ of ¥6.83 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Lionco Pharmaceutical Group Co's Total Liabilities for the quarter that ended in Mar. 2026 was ¥498.4 Mil.

Lionco Pharmaceutical Group Co's quarterly Total Liabilities increased from Sep. 2025 (¥465.93 Mil) to Dec. 2025 (¥486.50 Mil) and increased from Dec. 2025 (¥486.50 Mil) to Mar. 2026 (¥498.43 Mil).

Lionco Pharmaceutical Group Co's annual Total Liabilities declined from Dec. 2023 (¥693.52 Mil) to Dec. 2024 (¥485.57 Mil) but then increased from Dec. 2024 (¥485.57 Mil) to Dec. 2025 (¥486.50 Mil).

Lionco Pharmaceutical Group Co Total Liabilities Historical Data

* Premium members only.

The historical data trend for Lionco Pharmaceutical Group Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lionco Pharmaceutical Group Co Total Liabilities Chart

Lionco Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,055.53 720.84 693.52 485.57 486.50

Lionco Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 480.29 476.02 465.93 486.50 498.43
SHSE:603669
59GF Score
Lionco Pharmaceutical Group Co Ltd SHSE:603669
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lionco Pharmaceutical Group Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lionco Pharmaceutical Group Co's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=478.582+(2.131+5.784
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=486.5

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1106.779-620.282
=486.5

Lionco Pharmaceutical Group Co's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=472.575+(20.131+5.728
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=498.4

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=1121.672-623.238
=498.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ¥498.4 Mil mean?
Lionco Pharmaceutical Group Co (SHSE:603669) has a Total Liabilities of ¥498.4 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Lionco Pharmaceutical Group Co and its competitors.
Is Lionco Pharmaceutical Group Co's Total Liabilities too high?
Lionco Pharmaceutical Group Co's current Total Liabilities is ¥498.4 Mil. Overall, Lionco Pharmaceutical Group Co has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lionco Pharmaceutical Group Co's Total Liabilities compare to ZTS?
Lionco Pharmaceutical Group Co's Total Liabilities of ¥498.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Lionco Pharmaceutical Group Co and its competitors. Lionco Pharmaceutical Group Co's current Total Liabilities is ¥498.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lionco Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Lionco Pharmaceutical Group Co (SHSE:603669) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥6.83, compared to a current price of ¥5.04 — trading 26.2% below its estimated fair value. The current Total Liabilities is ¥498.4 Mil. Lionco Pharmaceutical Group Co's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Lionco Pharmaceutical Group Co (SHSE:603669), the current Total Liabilities is ¥498.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lionco Pharmaceutical Group Co (SHSE:603669) Overvalued in 2026?

Based on GuruFocus' analysis, Lionco Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥5.04 is trading 26.2% below its estimated GF Value™ of ¥6.83. GuruFocus considers Lionco Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for SHSE:603669:

  • Total Liabilities: ¥498.4 Mil
  • GF Value™: ¥6.83 vs. price of ¥5.04 (26.2% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the SHSE:603669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lionco Pharmaceutical Group Co Business Description

Address No. 20, National Highway 349, Naidong District, Shannan, CHN
Lionco Pharmaceutical Group Co Ltd is engaged in the research and development of medicines. The product portfolio includes - Alanyl glutamine for injection, fructose for injection, inverted sugar for injection, xylitol for injection, riboflavin sodium phosphate for injection, and water-soluble vitamin for injection.
59GF Score

Get the complete analysis for SHSE:603669

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.04
Price
¥6.83
GF Value